143 / 464
INTERDISCIPLINARY RADIOBIOLOGY CLINICAL BRACHYTHERAPY PHYSICS RTT YOUNG
143
Programme and Exhibition Guide |
SCIENTIFIC PROGRAMME
MONDAY 8 MAY 2017
combined treatment approach although several questions still remain to be solved.
Individualised medicine, including biomarkers and gene expression profiles could
help to decide whether radiation therapy is to be used and when. In fact, preoperative
radiation therapy is becoming favoured in some clinical situations, especially since it
allows a better understanding of its effects, such as exploiting possible immunological
effects of radiation. Finally the role of combining systemic treatments and radiation
therapy and its possible interactions will be addressed.
Chair: P.C. Lara Jimenez (Spain)
Co-chair: D. Kauer-Dorner (Austria)
14:45 > Personalised local and locoregional radiotherapy in breast cancer
Speaker: T. Tramm (Denmark)
SP-0476
15:15 > Where should we place radiotherapy: before or after surgery?
Speaker: L. Boersma (The Netherlands)
SP-0477
15:45 > Radiation therapy after complete response after primary systemic
therapy. Is it needed?
S
peaker: P. Poortmans (France)
SP-0478
SYMPOSIUMWITH PROFFERED PAPERS
Novel approaches in thoracic tumour treatment
14:45 - 16:15 | LEHAR 4
The session will give an update on current research on novel targeted drug
approaches to lung cancer treatment alone and in combination with radiotherapy.
The focus will be on prognostic and predictive factors, screening methods, Notch
signaling and the secretome.
Chair: P. Huber (Germany)
Co-chair: W. Raunik (Austria)
14:45 > Primary human Lung (stem) cell models to study adverse effects of
cancer treatments
M. Vooijs (The Netherlands)
SP-0479
15:10 > Secretome as novel target for lung cancer
M. Pruschy (Switzerland)
SP-0480
15:35 > Effects of nitroglycerin on perfusion and hypoxia in non-small cell lung
cancer lesions.
B. Reymen (The Netherlands), A.J.G. Even, C.M.L. Zegers, W. Van Elmpt,
M. Das, J. Wldberger, F. Mottaghy, E. Vegt, D. De Ruysscher, P. Lambin
OC-0481
15:45 > Interferon stimulated genes: a common pathway in tamoxifen- and
radioresistance in breast cancer